Clinical Trials Logo

Clinical Trial Summary

An open label, non-randomized study in pediatric patients with advanced high-grade gliomas and other solid tumors. The study will be performed in two phases: a dose escalation phase in up to 18 patients following a standard "3+3" design to establish dose-limiting toxicity (DLT) and a "safe" dose of LAM561 followed by an expanded safety cohort of up to 10 patients treated at the Maximum Tolerated Dose (MTD). If the MTD is well tolerated in the expanded safety cohort, that dose becomes the Recommended Phase 2 Dose (RP2D). Glioma patients and other solid tumor patients (including non-glial brain tumors) will be treated as a single cohort. Patients with either tumor type will be allowed to enroll on the study as positions are made available. No tumor type will be given priority over another and there is no minimum number of glioma patients or solid tumor patients that must be enrolled on the trial.


Clinical Trial Description

The dose of LAM561 each patient will receive will depend on the dose cohort into which they are enrolled. Once a patient is allocated a dose of LAM561 (either in the dose escalation phase or the expanded safety cohort), it is planned that they will continue to receive the same dose on a daily basis in treatment cycles of 21 days (3 weeks), which may be repeated continuously without therapy interruption, until any criterion for discontinuation is met (clinical or radiological progression of disease, clinically unacceptable toxicity, or another "general" discontinuation criterion is met as defined in Section 5.5). In the event of significant gastrointestinal toxicity, the treatment schedule may be modified from continuous dosing to an intermittent regime (e.g. 1 week of dosing followed by 1 week not dosing), except during Cycle 1 of the dose escalation phase. In the case of toxicity, the dose of LAM561 may be reduced or delayed by no more than 14 days at the discretion of the Investigator. Treatment "holidays" of no more than 14 days are also permitted for reasons other than toxicity, except during Cycle 1 of the dose escalation phase. Intra-patient dose escalation may be permitted in certain specific circumstances (and only if ≤ Grade 2 toxicity was observed during previous treatment cycles), but toxicity will not be considered for definition of DLT. It is expected that most patients will receive between one and 6 cycles of LAM561 for a treatment period of 3 to 18 weeks. The treatment period may be extended provided that no DLT has been observed and if in the opinion of the Investigator the patient is showing benefit from treatment with LAM561. Patients demonstrating clinical benefit from LAM561 will have the option of continuing treatment under compassionate use once the study has concluded. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04299191
Study type Interventional
Source Laminar Pharmaceuticals
Contact Adrian Gerald McNicholl
Phone +34971439886
Email clinical.dev@laminarpharma.com
Status Recruiting
Phase Phase 1/Phase 2
Start date September 1, 2020
Completion date November 2024

See also
  Status Clinical Trial Phase
Terminated NCT02305056 - Study of Tumor Metabolism by Isotopic Tagging in Patients With High-grade Glioma (CARBONOMIC) Phase 1
Not yet recruiting NCT06002711 - Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study
Terminated NCT00548938 - Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM Phase 2
Recruiting NCT05610891 - Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG Phase 1
Completed NCT01644773 - Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) Phase 1
Recruiting NCT02239952 - HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors) N/A
Completed NCT00565721 - A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Phase 2
Recruiting NCT05929456 - Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid) Phase 1
Recruiting NCT04552756 - Seizures During Radiotherapy for High-grade Gliomas N/A
Terminated NCT04730349 - A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer Phase 1/Phase 2
Completed NCT05873946 - Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery
Recruiting NCT02848794 - Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma Phase 1/Phase 2
Recruiting NCT06209567 - A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors Early Phase 1
Not yet recruiting NCT06201351 - Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction MRI
Recruiting NCT06118723 - The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Completed NCT00624728 - Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP) Phase 1/Phase 2
Terminated NCT04851834 - NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma Phase 1/Phase 2
Recruiting NCT04908267 - How the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade Gliomas
Completed NCT03458312 - Nurse-led Family and Network Consultations N/A
Not yet recruiting NCT04482933 - HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma Phase 2